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http://dx.doi.org/10.1016/j.jfma.201Despite proven good efficacy of pneumococcal conjugated vaccine in preventing invasive
pneumococcal disease, breakthrough infections remain a noticeable problem with significant
morbidity and mortality, especially in selected high-risk groups. We present a 2-year-old girl
with infantile spasm, who was treated with antiepileptic drugs and adrenocorticotropic
hormone (ACTH). Vaccination with three doses 7-valent pneumococcal conjugate vaccine
had been completed one month before ACTH therapy. Two months after ACTH therapy, she
suffered from fever, cough, and decreased activity. Streptococcus pneumoniae, serotype 6B,
was detected in blood culture. Vaccine failure could be possibly due to ACTH therapy.
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2.10.011Introduction
Streptococcus pneumoniae is a leading cause of serious
illness among children worldwide.1 Following widespread
use, the 7-valent pneumococcal conjugate vaccine (PCV7)
has led to remarkable decline in the incidence of invasive
pneumococcal disease (IPD) in the United States2 and& Formosan Medical Association. All rights reserved.
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and Prevention (CDC) showed that overall IPD rates among
children aged 5 years or less in 2005 were 77% lower
compared with the years preceding vaccine introduction
(1998e1999).3 However, because the protective efficacy of
the vaccine is not 100%, a small proportion of vaccinated
children will still get invasive pneumococcal infections.
Underlying diseases such as malignancies and immunodefi-
ciencies may or may not exist in vaccinated children with
breakthrough pneumococcal infections.4e6 Here, we
present a case of PCV7 failure in a 2-year-old girl who
received adrenocorticotropic hormone (ACTH) therapy for
infantile spasm.Case report
A girl aged 2 years and 4 months was hospitalized because
of fever for 3 days. During this time, mild cough and
a running nose were noted.
The patient was born at 36 weeks of gestation with
a birth weight of 2094 g (below the 10th percentile). The
Apgar scores were 7 and 9 at 1 minute and 5 minutes,
respectively. Results of newborn screening tests were
normal. Neonatal seizure and brain atrophy were found at
the age of 2 weeks. She was diagnosed as and treated for
infantile spasm. Antiepileptic drugs including vigabatrin,
lamotrigine, phenobarbital, and oxcarbazepine were used.
The first course of ACTH therapy (tetracosactide hex-
aacetate 0.025 mg/kg/dose per day for 2 weeks, tapered to
half frequency every 2 weeks for a total of 8 weeks) was
administered intramuscularly at the age of 1 year and 1
month. A second course of ACTH therapy (tetracosactide
hexaacetate 0.025 mg/kg/dose per day for 2 weeks and
0.025 mg/kg/dose every 2nd day for a week) was adminis-
tered at the age of 2 years and 2 months, but was dis-
continued due to hospitalization for bronchopneumonia.
There was no recent trauma, unusual ingestion, travel, or
exposure to animals. However, she had contact with
persons, including her parents, who had upper respiratory
tract infections. The child had attended well-child visits
and received routine immunizations. She also received
three doses of PCV7, at the age of 9 months, 10 months,
and 12 months.
On examination, the patient’s weight was 11.5 kg (about
the 25th percentile) and her height was 86 cm (about the
25th percentile). Her temperature was 36.6C, blood pres-
sure 118/54 mmHg, pulse 138/minute, and respiratory rate
34/minute. Her throat was hyperemic and a coarse
breathing sound was heard. As for neurologic development,
she had poor head control, could only stand with aid, and
only spoke a few words.
On laboratory investigation, hemoglobin was 11.4 g/dL,
leukocyte count was 40190/mm3, and platelet count was
388  103/mm3. Levels of liver enzyme, creatinine, and
sugar were all within normal limits except for a high C-
reactive protein level (12.62 mg/dL). Chest X-ray showed
focal consolidation in the right upper lung field. Both blood
and urine cultures were done on the day of admission.
Throat and rectal swabs were obtained for viral isolation.
She was initially treated with ampicillin-sulbactam
(ampicillin 150 mg/kg/day) for bronchopneumonia andantiepileptic drugs for infantile spasm. Fever resolved and
activity improved after using antibiotics. No bacterium was
isolated from urine and no virus was isolated from throat
and rectal swabs. The blood culture yielded S. pneumoniae.
The minimal inhibitory concentration was 1 mg/mL for
penicillin. After treatment with 5 days ampicillin-
sulbactam, then 4 days penicillin G (0.4 MU/kg/day), the
girl was discharged. Serotyping for S. pneumoniae isolate
was performed by the Quellung reaction with antisera from
Statens Serum Institute, Copenhagen, Denmark. It revealed
serotype 6B.Discussion
Due to biologic variability, probably none of the current
vaccines can achieve an absolute (100%) efficacy. In early
clinical trials, the PCV7 was reported to have a 97.4%
protective efficacy against invasive vaccine-type pneumo-
coccal diseases.7 Early reports showing failures of PCV7
were frequently associated with incomplete vaccinations or
underlying conditions such as HIV infections or chemo-
therapies for malignancies.5,8,9 Lower antibody concentra-
tion alone is not a sufficient factor for vaccine failure.
Antibody concentration, functional activity, and avidity all
play important roles.10
ACTH was used for treating infantile spasm since 1958
because conventional anticonvulsants were usually inef-
fective. ACTH stimulates the adrenal gland to release
cortisol and, to a lesser extent, aldosterone and andro-
gens. Reduced antibody response to polysaccharide
vaccine was reported in patients on glucocorticoid therapy
for nephrotic syndrome but not for asthma.11,12 The girl
presented here received ACTH therapy about 1 month after
the third PCV7 dose. The corticosteroid surge induced by
ACTH might have compromised a proper immune response
to the PCV7. As far as we know, this is the first report of
PCV7 failure in a child receiving ACTH therapy for infantile
spasm.
The current PCV7 contains 2 mg of protein-conjugated
polysaccharide for 4, 9V, 14, 18C, 19F, 23F and 4 mg for 6B.
6B is less immunogenic and needs a higher content.13 An
immunogenicity study of the PCV7 among 56 toddlers in
Taiwan revealed that the post-booster antibody concen-
trations exceed 0.2 mg/mL for all serotypes except 6B.14
Although we did not have a chance to determine the
antibody titers against S. pneumoniae before the bacter-
emia in this case, we reckon suboptimal antibody response
to 6B after ACTH therapy might have led to a breakthrough
S. pneumoniae infection in this case.
Recommendations for immunization of children at high
risk of pneumococcal disease were published in 2000.15 For
children 23 months and younger, the PCV7 vaccine is
administered at the age of 2 months, 4 months, 6 months,
and 12e15 months. For children 24e59 months old who
have received no previous doses, two doses of PCV7 are
recommended. It should be given at an interval of 6e8
weeks, followed by a single dose of 23-valent poly-
saccharide vaccine no less than 6e8 weeks after the last
dose of PCV7. An additional dose of 23-valent poly-
saccharide vaccine is recommended 3e5 years after the
last dose. The catch-up dose(s) depends on the age and the
232 M.-H. Lee et al.previous dose(s) that the host had received. The child we
present here received three doses of PCV7, which is in line
with the standard catch-up schedule for healthy infants of
6e12 months old. However, such a vaccination schedule
might be inadequate for immunocompromised children.
Additional doses of PCV7 or 23-valent polysaccharide
vaccine is necessary if children with ACTH therapy are
considered immunocompromised.
This case report highlights the problem of PCV7 catch-up
vaccinations in infants receiving ACTH therapy. Vaccine
failures may occur. Clinicians are encouraged to give chil-
dren with ACTH therapy for infantile spasm complete
pneumococcal vaccinations, including complete doses of
PCV7 and a dose of 23-valent polysaccharide vaccine.
Studies on immunogenicity of PCV7 in children under ACTH
therapy may provide insights into the issue.References
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